中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.018 seconds)

    Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide
    7.
    发明申请
    Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide 审中-公开
    能够产生VEGF结合融合多肽的细胞培养物组合物

    公开(公告)号：US20130084635A1

    公开(公告)日：2013-04-04

    申请号：US13683216

    申请日：2012-11-21

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Nicholas J. PAPADOPOULOS ,  Samuel DAVIS ,  George D. YANCOPOULOS

    IPC: C07K14/71

    CPC classification number: C07K14/71 ,  A61K38/00 ,  C07H21/04 ,  C07K16/22 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/30 ,  C12N15/09 ,  C12N15/10

    Abstract: The present invention provides cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.

    Abstract translation: 本发明提供能够产生结合血管内皮生长因子（VEGF）的融合多肽的细胞培养组合物。 本发明的细胞培养组合物包含含有包含编码结合VEGF的融合多肽的核酸分子的表达载体的细胞。 融合多肽可以包含具有第一VEGF受体的免疫球蛋白样（Ig）结构域2，第二VEGF受体的Ig结构域3和多聚化成分的VEGF受体组分。

    INTERLEUKIN-2 PROPROTEINS AND USES THEREOF
    9.
    发明公开
    INTERLEUKIN-2 PROPROTEINS AND USES THEREOF 审中-公开

    公开(公告)号：US20230382969A1

    公开(公告)日：2023-11-30

    申请号：US18324380

    申请日：2023-05-26

    Applicant: Regeneron Pharmaceuticals, Inc.

    Inventor： Supriya PATEL ,  Tong ZHANG ,  Jiaxi WU ,  Aaron CHANG ,  Eric SMITH ,  Chia-Yang LIN ,  Samuel DAVIS

    IPC: C07K14/55 ,  A61P35/00

    CPC classification number: C07K14/55 ,  A61P35/00

    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2Rα moiety and a protease-cleavable linker, configured such that the IL2Rα moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.

Patent Agency Ranking